These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33145266)

  • 1. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
    Hou Z; Zhu K; Yang X; Chen P; Zhang W; Cui Y; Zhu X; Song T; Li Q; Li H; Zhang T
    Ann Transl Med; 2020 Sep; 8(17):1047. PubMed ID: 33145266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study.
    Geng Q; Shen H; Zhu W; Lu Y; Wang M; Jiang H; Li D
    Onco Targets Ther; 2020; 13():11529-11535. PubMed ID: 33204107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study.
    He W; Liao L; Hu D; Li B; Wang C; Qiu J; Liao Y; Liu W; Yang Z; Zhang Y; Yuan Y; Li K; Yuan Y; Zheng Y
    Ann Transl Med; 2020 Aug; 8(16):1000. PubMed ID: 32953800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
    Zhang G; Gong S; Pang L; Hou L; He W
    Front Oncol; 2021; 11():659217. PubMed ID: 34012920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
    Li T; Zhao J; Zhang S; Wang H; Sun L; Hu J
    J Cancer Res Ther; 2023 Feb; 19(1):57-63. PubMed ID: 37006043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    Li J; Qin S; Wen L; Wang J; Deng W; Guo W; Jia T; Jiang D; Zhang G; He Y; Ba Y; Zhong H; Wang L; Lin X; Yang J; Zhao J; Bai Y; Wu X; Gao F; Sun G; Wu Y; Ye F; Wang Q; Xie Z; Yi T; Huang Y; Yu G; Lu L; Yuan Y; Li W; Liu L; Sun Y; Sun Y; Yin L; Hou Z
    BMC Med; 2023 May; 21(1):173. PubMed ID: 37147645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
    Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
    Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study.
    Yanwei L; Feng H; Ren P; Yue J; Zhang W; Tang P; Shang X; Pang Q; Liu D; Chen C; Pan Z; Tao YZ
    Oncologist; 2020 Oct; 25(10):e1464-e1472. PubMed ID: 32342599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
    Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
    Front Immunol; 2022; 13():944062. PubMed ID: 36091003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial.
    Liu Q; Xu JY; Xu YH; Chen M; Deng LC; Wu JP; Zhou T; Zhang LQ; Tan J; Pu XX; Shang YL; Hua J; Li YQ; Cai W; Gu YL; Peng XC; Chan PC; Jabbour SK; Nam HS; Hua D
    Transl Lung Cancer Res; 2022 May; 11(5):832-844. PubMed ID: 35693282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
    Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
    BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
    Wu F; Zhang S; Xiong A; Gao G; Li W; Cai W; Su C; Chen X; Zhou F; Zhao J; Ren S; Zhou C
    Clin Lung Cancer; 2018 Nov; 19(6):e831-e842. PubMed ID: 30026059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
    Wang C; Huang M; Geng Q; Li W; Chang J; Tang W; Guo W
    Ther Adv Med Oncol; 2021; 13():17588359211039047. PubMed ID: 34484431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of apatinib in patients with recurrent uterine malignancy: a prospective, single-center, single-arm, phase 2 study.
    Ren Y; Wang T; Cheng X; Ke G; Huang Y; Yang H; Huang X; Tian W; Wang H
    Ann Transl Med; 2023 Jan; 11(2):106. PubMed ID: 36819505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma.
    Qiu H; Ke S; Cai G; Wu Y; Wang J; Shi W; Chen J; Peng J; Yu B; Chen Y
    Cancer Med; 2023 Jan; 12(1):213-222. PubMed ID: 35633045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
    Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.